Scholarlink

Aim <p>Immunonutritional impairment driven by chronic inflammation and metabolic dysregulation plays a significant role in the progression of diabetic kidney disease (DKD). The hemoglobin–albumin–lymphocyte–platelet (HALP) score is a biomarker reflecting immunonutritional status; however, its prognostic value in patients with advanced DKD remains uncertain.</p> Method <p>In this retrospective cohort study, 348 patients with stage 3–4 chronic kidney disease (CKD) secondary to type 2 diabetes mellitus (eGFR 15–59 mL/min/1.73&#xa0;m²) were included after screening 769 individuals (2012–2024). The primary endpoint was renal progression, defined as a ≥ 40% decline in eGFR or initiation of renal replacement therapy. HALP was initially categorized into tertiles to evaluate baseline differences. Subsequently, a ROC-derived cutoff was used to dichotomize patients into low- and high-HALP groups, followed by Kaplan–Meier and Cox regression analyses. Predictive performance was assessed using ROC analysis, and robustness was evaluated through subgroup analyses and 1:1 propensity score (PS) matching.</p> Results <p>Renal progression occurred in 181 patients. HALP components and urine protein creatinine ratio (UPCR) differed significantly across tertile groups (<i>p</i> &lt; 0.001 for components; <i>p</i> = 0.025 for UPCR). The ROC-derived cutoff was 34.15 (AUC 0.602; <i>p</i> = 0.001). After PS matching (<i>n</i> = 278), low-HALP group remained independently associated with an increased risk of renal progression (HR 1.627; <i>p</i> = 0.005). Subgroup analyses revealed no significant interaction, supporting the consistency of the findings across clinical strata.</p> Conclusion <p>The HALP score may serve as a simple, cost-effective and widely available adjunctive tool for risk stratification in patients with advanced DKD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HALP score and risk of renal progression in diabetic kidney disease

  • 期刊论文

  • 发表日期：

    2026年7月20日

查看全文
  • Muhammed Emre Sevim,
  • Pelda Zümrüt Sevim,
  • Fatma Yılmaz Aydın,
  • Şeyhmus Akçay,
  • Adnan Önün,
  • Yunus Avcı,
  • Zülfükar Yılmaz,
  • Yaşar Yıldırım,
  • Emre Aydın

摘要

Aim

Immunonutritional impairment driven by chronic inflammation and metabolic dysregulation plays a significant role in the progression of diabetic kidney disease (DKD). The hemoglobin–albumin–lymphocyte–platelet (HALP) score is a biomarker reflecting immunonutritional status; however, its prognostic value in patients with advanced DKD remains uncertain.

Method

In this retrospective cohort study, 348 patients with stage 3–4 chronic kidney disease (CKD) secondary to type 2 diabetes mellitus (eGFR 15–59 mL/min/1.73 m²) were included after screening 769 individuals (2012–2024). The primary endpoint was renal progression, defined as a ≥ 40% decline in eGFR or initiation of renal replacement therapy. HALP was initially categorized into tertiles to evaluate baseline differences. Subsequently, a ROC-derived cutoff was used to dichotomize patients into low- and high-HALP groups, followed by Kaplan–Meier and Cox regression analyses. Predictive performance was assessed using ROC analysis, and robustness was evaluated through subgroup analyses and 1:1 propensity score (PS) matching.

Results

Renal progression occurred in 181 patients. HALP components and urine protein creatinine ratio (UPCR) differed significantly across tertile groups (p < 0.001 for components; p = 0.025 for UPCR). The ROC-derived cutoff was 34.15 (AUC 0.602; p = 0.001). After PS matching (n = 278), low-HALP group remained independently associated with an increased risk of renal progression (HR 1.627; p = 0.005). Subgroup analyses revealed no significant interaction, supporting the consistency of the findings across clinical strata.

Conclusion

The HALP score may serve as a simple, cost-effective and widely available adjunctive tool for risk stratification in patients with advanced DKD.